Kristian Alissa Choate

Mrs. Kristian Alissa Choate


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Biology
Verified
Journal Article
Open access
PDF file
KCKristian Alissa Choate
Kristian Alissa Choate
EPEvan Pratt
Evan Pratt
MJMatthew Jennings
Matthew Jennings
RWRobert J. Winn
Robert J. Winn
PMPaul Barrie Mann
Paul Barrie Mann
In 2021, the World Health Organization classified isocitrate dehydrogenase (IDH) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an IDH mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. IDH enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of IDH mutations in gliomas as well as current diagnostic techniques.

7 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKristian Alissa Choate
Kristian Alissa Choate
EPEvan Pratt
Evan Pratt
MJMatthew Jennings
Matthew Jennings
RWRobert J. Winn
Robert J. Winn
PMPaul Barrie Mann
Paul Barrie Mann
In 2021, the World Health Organization classified isocitrate dehydrogenase (IDH) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an IDH mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. IDH enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of IDH mutations in gliomas as well as current diagnostic techniques.